BK0074 Traditional Chinese Medicine Ii
- 1221.320
- +1.290+0.11%
Guizhou Xinbang Pharmaceutical, the company that sold its products at a loss, is going to Hong Kong Stock Exchange.
The Hong Kong Stock Exchange IPO application wave may be imminent. Since May of this year, 22 companies have submitted IPO applications to the Hong Kong Stock Exchange, while the Shanghai and Shenzhen stock exchanges are still in a state of "0 acceptance" during the same period. As a member of the vast army of IPO applications, Taide Pharmaceutical (Zhejiang) Co., Ltd. (referred to as "Taide Pharmaceutical") is launching a sprint towards the Hong Kong Stock Exchange. The application materials showed that Taide Pharmaceutical mainly provides peptide new chemical molecular entity discovery synthesis (CRO) and peptide chemical production, manufacturing and control (CDMO) services to pharmaceutical companies. In the reporting period, Taide Pharmaceutical has already achieved profits. From 2021 to 2023.
2024 Financial Report | After the dividend ratio is close to 100%, Donga Ejiao still has 8 billion
Extravagant dividends
Review of December 24: full momentum this week, release the volume of the main funds to attack 5 shares next week.
December 24 news, the three major indices opened low, and then Prev maintained a low consolidation, the gem index led two cities down. In terms of the plate, medicine-related plates collectively rose, Chinese medicine stocks led the rise, food processing, retail and other consumer stocks were active against the trend; lithium batteries, photovoltaic, energy storage and other new energy tracks fell across the board, of which the weight fell more than 9% in the Ningde era. The index continued to weaken in the afternoon, with the gem index falling 2.7% at one point. Cultivate diamond, NFT concept stocks pull up; automobile, rare earth, fluorine chemical industry, digital currency and other sectors in the doldrums. Overall, market sentiment cooled, individual stocks showed a general downward trend, the two markets
Guangdong Lifestrong Pharmacy Targets $66 Million in Shenzhen IPO
06:08 PM EST, 11/25/2021 (MT Newswires) -- Guangdong Lifestrong Pharmacy (SHE:301111) is seeking to raise as much as 419.2 million yuan ($65.6 million) from its initial public offering on the Shenzhe
Market Chatter: Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms
10:50 PM EST, 11/21/2021 (MT Newswires) -- A Chinese court's recent decision to sentence former Kangmei Pharmaceutical (SHA:600518) Chairman Ma Xingtian and other directors to jail over securities fr
Guangdong Lifestrong Pharmacy Launches Shenzhen IPO
06:13 PM EST, 11/17/2021 (MT Newswires) -- Guangdong Lifestrong Pharmacy (SHE:301111) has launched its initial public offering on the Shenzhen Stock Exchange's ChiNext board on Wednesday. The Chinese
Ban Loong Gets $164 Million Takeover Bid from Yunnan Baiyao
07:13 AM EDT, 11/05/2021 (MT Newswires) -- Ban Loong Holdings (HKG:0030) received a takeover bid from its largest shareholder Yunnan Baiyao Group or YNBY (SHE:000538), according to a late Thursday bo
Dong-E-E-Jiao Swings to Profit in January-September
11:28 PM EDT, 10/31/2021 (MT Newswires) -- Dong-E-E-Jiao (SHE:000423) turned to 302.4 million yuan ($47.2 million) profit in January to September, rebounding from a loss of 20.9 million yuan a year
Jiangzhong Pharma's January-September Profit Jumps 14%
12:56 AM EDT, 10/28/2021 (MT Newswires) -- Jiangzhong Pharmaceutical's (SHA:600750) net profit for the nine months ended Sept. 30 rose 13.5% year-over-year to 466.4 million yuan ($72.9 million) from
Baiyunshan Pharmaceutical's Q3 Profit Jumps 10%
04:45 AM EDT, 10/27/2021 (MT Newswires) -- Guangzhou Baiyunshan Pharmaceutical Holdings' (SHA:600332, HKG:0874) third-quarter net profit slumped 9.55% from a year earlier to 809.4 million yuan ($126.
China Resources Sanjiu Logs Higher Net Profit, Revenue in January-September; Shares Slump 10%
03:06 AM EDT, 10/27/2021 (MT Newswires) -- China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) posted a net profit of 1.76 billion yuan ($275.7 million) in the nine months ended Sept. 30
Dong-E-E-Jiao Forecasts Up to 164% Surge in Q3 Profit
03:17 AM EDT, 10/15/2021 (MT Newswires) -- Dong-E-E-Jiao (SHE:000423) expects third-quarter net profit to range between 131.5 million yuan and 166.7 million yuan ($20.5 million to $26 million), which
Xu Shuqing, former chairman of Zhongheng Group, retried the divorce case.
On Friday, September 24, Zhongheng Group opened low and continued to fall in the afternoon. By the end of the day, it was down 2.55%, with a quotation of 3.44 yuan per share. On September 23, Xu Shuqing, former chairman of Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as Zhongheng Group), divorced and analyzed the case, which was retried by Guangxi Wuzhou Wanxiu District Court in Hunan Women's Prison. The divorce case is complicated and confusing, involving bribery, embezzlement, misappropriation of funds and other charges. Zhang Songcheng is Xu Shuqing's second husband. The couple married in August 2000 and divorced in April 2009. Zhongheng Group 20
Tailong Pharmaceutical Co., Ltd. plans to welcome the new owner, Zhengzhou high-tech production investment is planned to become the actual controller.
On September 23rd, Capital State learned that the controlling shareholder of A-share company Tai long Pharmaceutical (600222.SH) signed the "share transfer Framework Agreement". As of the date of this announcement, Zhengzhou Zhongsheng Industrial Group Co., Ltd. (hereinafter referred to as "Zhongsheng Industry"), the company's controlling shareholder, holds 132 million shares of the company, accounting for 23.08% of the company's total share capital, all of which are tradable shares with unlimited sales conditions. Zhongsheng Industries has pledged a total of 50 million shares of the company, accounting for 37.75% of the shares held and 8.71% of the total share capital of the company. The above-mentioned stock pledge is not expected to pose an obstacle to the progress of the transaction.
Zhong Cang Wanhua Chemical made a huge profit of more than 5 billion Niusan, and now he is doing it again!
Retail investors account for the largest number of investors in A-shares, with data showing that by the end of August 2021, the number of A-share investors had reached 192 million, of which more than 99 per cent were natural persons, also known as retail investors. Compared with institutions, retail investors have a relatively low level of investment. However, because of the large number, many retail investors are also born a lot of cattle scattered, that is, a high level of technology, a huge position of the natural person. When it comes to scattered, we have to mention Sun Huigang, who became famous because of his heavy position of CRRC Corporation, and later made a huge profit of more than 5 billion because of Chong Cang Wanhua Chemical Co., Ltd. Recently, he once again aroused widespread concern in the market.
On September 15, 10 companies including Angel Yeast and Yan'an Bikang announced favorable results
1. Angel Yeast: Angel Yeast announced that it intends to establish a joint venture with Kang Helong to develop the baby snack food business. In order to promote the rapid development of the baby snack food business segment, Angel News plans to establish a joint venture with Kang Helong. The joint venture will seek new opportunities for development in the field of infant snack food as a holding subsidiary specializing in the development of products related to the snack food industry by Angel Newt. 2. Poinsettia: The wholly-owned subsidiary obtained the bromhexine hydrochloride injection registration certificate. The wholly-owned subsidiary obtained the bromhexine hydrochloride injection registration certificate. 3. Qianjing Garden: Won the bid 67
Sept. 8 Taian Tang trading analysis: Internet health care, assisted reproduction, traditional Chinese medicine concept hot stocks
Securities Star data Center News, Taian Tang rose the limit to close, closing price 6.22 yuan. The stock rose by the limit at 09:47 and opened once, with a closing fund of 35.4148 million yuan, accounting for 0.76% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 79.9379 million yuan, the net inflow of hot capital was 86.2267 million yuan, and the net outflow of retail funds was 37.4142 million yuan. The flow of funds in the past five days is shown in the following table: this unit is a hot stock of Internet medical care, assisted reproduction and traditional Chinese medicine concept. On the same day, the Internet medical concept rose 1.12%, and the concept of assisted reproduction rose 0.6%.
Guang Yuanyuan impact two consecutive trading limit, investors are expected to lift the trap?
Guang Yuyuan, once a traditional Chinese medicine "demon stock", has finally ushered in a rising momentum after a substantial adjustment, and continues to hit the limit today after yesterday's limit. It can be said that the stock price, which is well-known for its two major concepts, has experienced a roller coaster in recent months. For its hype, it began with the difficulty of finding a tablet of Pian Tsai Yi, and then Yunnan Baiyao was also hyped, and then the market began to look for relatively undervalued stocks of traditional Chinese medicine, and the wide reputation was speculated by funds under this background. Similar to the top secret formula of Yunnan Baiyao and pianzi, Guangyuanyuan also has the age of turtles.
Analysis of the daily limit of essential Pharmaceuticals on Sept. 6: PD-1 Inhibitors, traditional Chinese Medicine, Pharmaceutical concept Hot stocks
Securities Star data center news, the essence of pharmaceutical trading closed, the closing price of 6.68 yuan. The stock rose by the daily limit at 09:25, but did not open the limit. The closing capital was 76.519 million yuan, accounting for 1.38% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 14.3163 million yuan, the net inflow of hot capital was 17.3811 million yuan, and the net outflow of retail funds was 8.2338 million yuan. The capital flow in the past five days is shown in the following table: the stock is a PD-1 inhibitor, traditional Chinese medicine and pharmaceutical concept hot stocks. On the same day, the concept of PD-1 inhibitor rose 3.05%, and the concept of traditional Chinese medicine rose 2.72%.
Analysis of Guanyuyuan trading limit on September 6: liquor, traditional Chinese medicine, pharmaceutical concept hot stocks
Securities Star data Center News, widely known as the limit to close, the closing price of 30.24 yuan. The stock rose by the daily limit at 09:48, but did not open the limit. The closing capital was 123 million yuan, accounting for 0.83% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 112 million yuan, the net inflow of hot capital was 104 million yuan, and the net outflow of retail funds was 64.2861 million yuan. In the past 5 days, the capital flow is shown in the following table: the stock is a hot stock of liquor, traditional Chinese medicine and pharmaceutical concepts. On the same day, the concept of liquor rose 4.22%, the concept of traditional Chinese medicine rose 2.72%, and the concept of medicine rose 2.4%. The stock investment